FDA pharm team
Executive Summary
An "ideal background for going into industry would be to have worked at the FDA for awhile," Novartis Oncology VP-Clinical Research David Parkinson, MD, told fellows at a career panel during the American Society of Clinical Oncology annual meeting May 15. "Even more ideal is if you got to...the FDA having worked as a clinical investigator for a while. I think those are the best kind of people. Those are the people we like to deal with because they know the business"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth